Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Core Insights - Senti Biosciences, Inc. reported significant progress in 2025, focusing on developing next-generation cell and gene therapies through its Gene Circuit platform, with SENTI-202 as the lead program showing positive clinical data [2][6] Recent Pipeline and Corporate Updates - The company reported updated positive preliminary clinical data from the ongoing Phase 1 trial of SENTI-202 in relapsed/refractory acute myeloid leukemia (AML), indicating encouraging response rates, durability, and a favorable safety profile [6] - Senti Bio received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for SENTI-202 for treating adults with relapsed or refractory AML [6] - The company is advancing its pipeline and synthetic biology platform, with progress across its Gene Circuit-engineered cell therapy programs [6] Year 2025 Financial Results - As of December 31, 2025, Senti Bio held cash and cash equivalents of approximately $16.4 million, a decrease from $48.3 million in 2024 [10] - Research and development expenses for the full year of 2025 were $37.6 million, while general and administrative expenses totaled $26.2 million [6][11] - The net loss for the three months ended December 31, 2025, was $14.5 million, or $0.53 per share, and the full-year net loss was $61.4 million, or $2.73 per share [6][12]